drugset / Trial / NCT01324388

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388

Phase 1 Completed 51 enrolled Eli Lilly and Company
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2. To evaluate the effect of LY2189265 on heart rate and blood pressure in healthy volunteers when taken with a Beta-blocker drug (metoprolol). In Part 1, participants will receive four weekly injections of LY2189265 with continued use of normal lisinopril therapy. Part 2 is a cross-over study design. Participants will receive a single injection of LY2189265 in one period, and seven daily doses of metoprolol and a single injection of LY2189265 in another period.

Timeline

Start
2011-03
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 1.5 mg Subcutaneous
Subject LISINOPRIL ANHYDROUS Small molecule Oral
Subject Metoprolol Other / unclassified 100 mg Oral